Share on

Global Therapeutic Vaccines Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Disease Type & Region - Industry Forecast (2022 to 2027)

Published: January, 2022
ID: 54
Pages: 177
Formats: report pdf report excel report power bi report ppt

Therapeutic Vaccines Market Size (2022 to 2027)

The size of the global therapeutic vaccines market is predicted to be worth USD 15356 million by 2027 from USD 3607 million in 2022, growing at a CAGR of 33.6% from 2022 to 2027. Several approaches are being developed in the pipeline to boost the immune response to various infectious and cancerous cells.

The therapeutic vaccines market is different from any other product market. Compared to the pharmaceutical market, it is relatively small, although growing at a fast rate. There are presently close to 120 new vaccines in the pipeline of various multinational companies across the globe set to hit the market in the next few years. The vaccine market is relatively concentrated on both the supply and demand sides. It is highly regulated and mostly dependent on public purchasers and donor policies. It has very distinct features that increase the complexity of assessing and understanding pricing and procurement in their context.


Increased government funding for vaccine development, increased investments by major market players, increasing disease prevalence, technological advances, and NGOs' initiatives are some of the factors driving the global therapeutic vaccines market forward.

Due to the increasing incidence of diseases like cancer and HIV, therapeutic vaccines have become more popular. Some of the key factors driving the growth of the global therapeutic vaccines market are technological advances in HIV diagnosis and increased clinical trials for HIV and cancer vaccines. Furthermore, rising public awareness of serious diseases and increased R&D investments in therapeutic vaccines boost the therapeutic vaccines market growth.

An increase in funding’s from the government for vaccine development, a rise in investments by the major market players, rising prevalence of the disease, technological advancements, initiatives by NGOs are some of the factors that are propelling the market growth.

The significant increase in the prevalence of various chronic diseases, such as cancer, HIV, and cardiovascular diseases, has significantly impacted the global market for therapeutic vaccines. The alarming rise in the demand for effective treatment has shifted global attention to therapeutic vaccines. Several pharmaceutical companies have begun developing novel vaccines for breast cancer, lung cancer, and Alzheimer's disease. Even though these innovations are still in the pipeline and have yet to be commercialized, they point to a new opportunity for the global therapeutic vaccine market. In addition, human papillomavirus-mediated cancers will present a growth opportunity for the global therapeutic vaccines market.


However, massive capital expenditures and stringent regulatory policies, and high costs associated with treatment are few factors inhibiting the market's growth. The global therapeutic vaccines market is restricted by higher vaccine costs and a lack of therapeutic drug availability. Furthermore, the global therapeutic vaccines market is hampered by strict regulatory requirements for therapeutic vaccine approval. The market is being limited by inefficient research and development and reimbursement policies. However, the vaccine can treat a wide range of chronic diseases; these constraints will weaken over time.

Adverse side effects of therapeutic vaccination and lack of awareness may threaten the global therapeutic vaccines market's expansion. Market growth will be hampered by issues such as the high cost of developing therapeutic vaccines. There is, however, one challenge in this situation. Vaccine R&D takes a long time and requires a lot of money, just like drug development. Clinical trials must be completed before a vaccine can be released commercially. The majority of vaccines are rejected at each stage of the clinical trial. By the time the final product is approved for commercial use, a significant amount of money has been spent on the vaccine development R&D process. These are the challenges faced by the market.

Impact of Covid-19 on the global therapeutic vaccines market:

As the COVID-19 virus spreads around the world, countries and medical regulators will speed up vaccine development. Due to the impact of the COVID-19 pandemic in the first half of 2020, the global therapeutic vaccines market is expected to expand by USD 3.78 billion, a substantial increase over 2019 growth estimates. A therapeutic vaccine is a combination of biologics used to develop immunity against abnormal cells in the body. Therapeutic vaccines can be customized to the patient's needs and used to treat a variety of disorders and diseases, including cancer, HIV infection, and Alzheimer's disease. New vaccines that target various types of cancers are growing rapidly amid the focus on COVID vaccines. Therapeutic vaccines aid in the treatment of diseases by inducing or strengthening the immune response. However, the therapeutic vaccine market has been held back by a small number of well-established therapeutic vaccines with well-studied properties. Various studies and demand for biologics have resulted in a major shift in the growth graph toward high value. As a result, the Therapeutic vaccine market has had positive growth during the forecast period.




Market Size Available

2021 to 2027

Base Year


Forecast Period

2022 to 2027

Segments Covered

By Disease Type and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia-Pacific, Latin America, Middle East & Africa

Market Leaders Profiled

GlaxoSmithKline, plc., Merck and Company, Bavarian Nordic, CSL Limited, Emergent BioSolutions Inc., Novartis AG, Johnson and Johnson, MedImmune, LLC, Pfizer, Inc., and Sanofi Pasteur.


This research report on the global therapeutic vaccines market has been segmented and sub-segmented based on the disease type and region.

Therapeutic Vaccines Market - By Disease Type:

  • Autoimmune Disease Vaccines      
  • Cancer Vaccines   
    • Multikine
    • PR1 Peptide
    • Truax
    • CYT004-MelQbG10
  • Neurological Disease Vaccines        
    • ACC- 001
    • CAD 106
    • Parkinson's Vaccine
    • Alzheimer's Vaccine
  • Infectious Disease Vaccines             
    • Hepatitis C Vaccines
    • HIV/AIDS Vaccines
    • Other Infectious Disease Vaccines

Based on the disease type, autoimmune disease vaccines are holding dominant shares of the market. Increasing prevalence for the manufacturing of various vaccines for different diseases to promote significant results primarily accelerates the demand for the market. People's interest in innovative developments with the latest technologies is significantly influencing the demand of the market. The rise in the need for targeted diseases is also surging the growth of the market. Therapeutic vaccines are highly effective in treating the disease with fewer or no side effects, which are also ascribed to bolster the market's growth rate. The market is also to grow with the increasing support from the private and public organizations on healthcare centers.

Therapeutic Vaccines Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

North America is witnessed in leading dominant market shares, with the rise in patients' flow suffering from chronic diseases. Acceptance of advanced technology and the launch of new products in favor of the end-users are likely to outshine the demand of the therapeutic vaccines market in this region. Growing awareness over the availability of different therapies among individuals is escalating the growth of the market. Stringent rules and regulations by the government are also an attribute lavishing the development of the market. The U.S.A is the major country contributing to the highest shares for the market in North America. The increased production rate of the vaccines and the growing development of new vaccines in research centers are significant factors for the market growth in the USA. Europe is positioned next to North America in leading prominent shares of the market. An increase in the deaths of women and children due to autoimmune disease is solely to leverage the market demand. The rising scale of healthcare centers with new techniques for chronic and fatal diseases is accelerating the market demand in this region.

Asia Pacific has had a tremendous growth rate from the past decade and hit the highest CAGR in the near future. The rise in the geriatric population and growing concern towards health is elevating the growth of the market. Also, increasing disposable income in urban areas is spurring the growth rate of the therapeutic vaccines market.


Some of the prominent companies influencing the global preventive vaccine market are GlaxoSmithKline, plc., Merck and Company, Bavarian Nordic, CSL Limited, Emergent BioSolutions Inc., Novartis AG, Johnson and Johnson, MedImmune, LLC, Pfizer, Inc., and Sanofi Pasteur.

Multinational vaccine companies have historically conducted much of the innovation, research, and development in vaccine production. They have used significant revenues, global size, and more profound expertise to fund.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample